Original Contribution

Basic Research in Cardiology

, 108:326

First online:

Interferon regulatory factor 3 is a negative regulator of pathological cardiac hypertrophy

  • Jing LuAffiliated withDepartment of Cardiology, Renmin Hospital, Cardiovascular Research Institute, Wuhan University
  • , Zhou-Yan BianAffiliated withDepartment of Cardiology, Renmin Hospital, Cardiovascular Research Institute, Wuhan University
  • , Ran ZhangAffiliated withNational Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College
  • , Yan ZhangAffiliated withDepartment of Cardiology, Renmin Hospital, Cardiovascular Research Institute, Wuhan University
  • , Chen LiuAffiliated withDepartment of Cardiology, The First Affiliated Hospital, Sun Yat-sen University
  • , Ling YanAffiliated withDepartment of Cardiology, Renmin Hospital, Cardiovascular Research Institute, Wuhan University
  • , Shu-Min ZhangAffiliated withDepartment of Cardiology, Renmin Hospital, Cardiovascular Research Institute, Wuhan University
  • , Ding-Sheng JiangAffiliated withDepartment of Cardiology, Renmin Hospital, Cardiovascular Research Institute, Wuhan University
  • , Xiang WeiAffiliated withDepartment of Thoracic and Cardiovascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    • , Xue Hai ZhuAffiliated withDepartment of Thoracic and Cardiovascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    • , Manyin ChenAffiliated withDivision of Cardiology, Heart and Stroke/Richard Lewar Centre of Excellence, University of Toronto
    • , Ai-Bing WangAffiliated withLaboratory of Molecular Cardiology, NHLBI, National Institutes of Health
    • , Yingjie ChenAffiliated withCardiovascular Division, University of Minnesota
    • , Qinglin YangAffiliated withDepartment of Nutrition Sciences, University of Alabama at Birmingham
    • , Peter P. LiuAffiliated withDivision of Cardiology, Heart and Stroke/Richard Lewar Centre of Excellence, University of Toronto
    • , Hongliang LiAffiliated withDepartment of Cardiology, Renmin Hospital, Cardiovascular Research Institute, Wuhan University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Interferon regulatory factor (IRF) 3, a member of the highly conserved IRF family transcription factors, plays a pivotal role in innate immune response, apoptosis, and oncogenesis. Recent studies have implicated IRF3 in a wide range of host defense. However, whether IRF3 induces defensive responses to hypertrophic stresses such as biomechanical stress and neurohumoral factors remains unclear. Herein, we employed an IRF3-deficient mouse model, cardiac-specific IRF3-overexpression mouse model and isolated cardiomyocytes to investigate the role of IRF3 in cardiac hypertrophy induced by aortic banding (AB) or isoproterenol (ISO). The extent of cardiac hypertrophy was quantitated by echocardiography as well as by pathological and molecular analysis. Our results demonstrate that IRF3 deficiency profoundly exacerbated cardiac hypertrophy, whereas overexpression of IRF3 in the heart significantly blunted pathological cardiac remodeling induced by pressure overload. Similar results were also observed in cultured cardiomyocytes upon the treatment with ISO. Mechanistically, we discovered that IRF3 interacted with ERK2 and thereby inhibited the ERK1/2 signaling. Furthermore, inactivation of ERK1/2 by U0126 offset the IRF3-deficient-mediated hypertrophic response induced by aortic banding. Altogether, these data demonstrate that IRF3 plays a protective role in AB-induced hypertrophic response by inactivating ERK1/2 in the heart. Therefore, IRF3 could be a new target for the prevention and therapy of cardiac hypertrophy and failure.

Keywords

IRF3 Hypertrophy Remodeling Signal transduction ERK1/2